A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Emerging MS Treatments: Reading the Gilenya Tea Leaves," includes profiles of Allozyne, GeNeuro, Nuron Biotech and Receptos. Plus these Start-Ups Across Health Care: Intralink-Spine, NinePoint Medical, PanOptica and Urovalve.
Allozyne Inc.'s novel interferon beta drug candidate is now in Phase I clinical trials for MS. The company used its proprietary linker technology to attach PEG to interferon, and believes that will allow more drug to be loaded into a dose and lead to a product that could be injected as infrequently as once per month. Moreover, it thinks its PEG conjugate should reduce tolerance problems and improve half-life over current interferons.
[A#IV003599]
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
